{"id":"https://openalex.org/W2118256381","doi":"https://doi.org/10.1158/1535-7163.mct-12-0995","title":"BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer","display_name":"BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer","alternate_titles":[],"publication_year":2013,"publication_date":"2013-06-01","ids":{"openalex":"https://openalex.org/W2118256381","doi":"https://doi.org/10.1158/1535-7163.mct-12-0995","mag":"2118256381","pmid":"https://pubmed.ncbi.nlm.nih.gov/23729403","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3681897"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-12-0995","doi":"https://doi.org/10.1158/1535-7163.mct-12-0995","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-12-0995","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2118256381"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://europepmc.org/articles/PMC3681897","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101402722","display_name":"Bercin Kutluk Cenik","orcid":"https://orcid.org/0000-0003-1260-6512","observed_orcids":["https://orcid.org/0000-0003-1260-6512"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bercin Kutluk Cenik","raw_affiliation_strings":["Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021634992","display_name":"Katherine T. Ostapoff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Katherine T. Ostapoff","raw_affiliation_strings":["Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055537555","display_name":"David E. Gerber","orcid":"https://orcid.org/0000-0002-7812-6741","observed_orcids":["https://orcid.org/0000-0002-7812-6741"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David E. Gerber","raw_affiliation_strings":["Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089104361","display_name":"Rolf A. Brekken","orcid":"https://orcid.org/0000-0003-2704-2377","observed_orcids":["https://orcid.org/0000-0003-2704-2377"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rolf A. Brekken","raw_affiliation_strings":["Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Hamon Center for Therapeutic Oncology Research, Divisions of 2Surgical Oncology, Department of Surgery, 3Hematology and Oncology, Department of Internal Medicine, and 4Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas","institution_ids":["https://openalex.org/I867280407"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I867280407"],"apc_list":null,"apc_paid":null,"fwci":3.5972,"has_fulltext":false,"cited_by_count":96,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94931846,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"12","issue":"6","first_page":"992","last_page":"1001"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nintedanib","display_name":"nintedanib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/angiokinase-inhibitors","display_name":"angiokinase inhibitors","score":0.7020000219345093},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.8560000061988831},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":1.0},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.9819999933242798},{"id":"https://openalex.org/keywords/epithelial-mesenchymal-transition","display_name":"epithelial-mesenchymal transition","score":0.9919999837875366},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.902999997138977},{"id":"https://openalex.org/keywords/vegf-receptors","display_name":"VEGF receptors","score":0.8309999704360962},{"id":"https://openalex.org/keywords/pdgf-receptor","display_name":"PDGF receptor","score":0.7300000190734863},{"id":"https://openalex.org/keywords/fibroblast-growth-factor-receptor","display_name":"fibroblast growth factor receptor","score":0.777999997138977},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6610000133514404},{"id":"https://openalex.org/keywords/microvessel-density","display_name":"microvessel density","score":0.7870000004768372},{"id":"https://openalex.org/keywords/pericyte-coverage","display_name":"pericyte coverage","score":0.675000011920929},{"id":"https://openalex.org/keywords/tumor-perfusion","display_name":"tumor perfusion","score":0.5569999814033508},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C2780171596","wikidata":"https://www.wikidata.org/wiki/Q15149723","display_name":"Nintedanib","level":4,"score":0.7410560846328735},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.5553966164588928},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5349339842796326},{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.45935797691345215},{"id":"https://openalex.org/C26375932","wikidata":"https://www.wikidata.org/wiki/Q118226","display_name":"Growth factor receptor","level":3,"score":0.43009358644485474},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42477428913116455},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.41511696577072144},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4124853312969208},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35406458377838135},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34238988161087036},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2672841250896454},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.2385631799697876},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2355075180530548},{"id":"https://openalex.org/C2778341716","wikidata":"https://www.wikidata.org/wiki/Q2290446","display_name":"Idiopathic pulmonary fibrosis","level":3,"score":0.2043679654598236},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1832112967967987},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.1207021176815033},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.08319437503814697}],"mesh":[{"descriptor_ui":"D000860","descriptor_name":"Hypoxia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017468","descriptor_name":"Receptors, Fibroblast Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017468","descriptor_name":"Receptors, Fibroblast Growth Factor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017479","descriptor_name":"Receptors, Platelet-Derived Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017479","descriptor_name":"Receptors, Platelet-Derived Growth Factor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053148","descriptor_name":"Caspase 3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058750","descriptor_name":"Epithelial-Mesenchymal Transition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1158/1535-7163.mct-12-0995","doi":"https://doi.org/10.1158/1535-7163.mct-12-0995","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-12-0995","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:23729403","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23729403","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:3014157","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3681897","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3681897","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3681897/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.936.5637","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.936.5637","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/early/2013/05/30/1535-7163.MCT-12-0995.full.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.960.8696","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.960.8696","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/12/6/992.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3014157","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3681897","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5746294","display_name":"Targeting Lung Cancer Vulnerabilities","funder_award_id":"P50CA070907","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W1534920898","https://openalex.org/W1970424863","https://openalex.org/W1977999028","https://openalex.org/W1979858258","https://openalex.org/W1987486152","https://openalex.org/W1988307856","https://openalex.org/W1990622503","https://openalex.org/W2009366489","https://openalex.org/W2014370165","https://openalex.org/W2017322644","https://openalex.org/W2019214567","https://openalex.org/W2031850848","https://openalex.org/W2036418044","https://openalex.org/W2048967458","https://openalex.org/W2050089891","https://openalex.org/W2063466980","https://openalex.org/W2063874384","https://openalex.org/W2076812945","https://openalex.org/W2083210150","https://openalex.org/W2089431977","https://openalex.org/W2089756110","https://openalex.org/W2095867755","https://openalex.org/W2098891057","https://openalex.org/W2100785570","https://openalex.org/W2102056525","https://openalex.org/W2111599976","https://openalex.org/W2112524831","https://openalex.org/W2112940666","https://openalex.org/W2115078104","https://openalex.org/W2115898240","https://openalex.org/W2118362228","https://openalex.org/W2120807407","https://openalex.org/W2124143152","https://openalex.org/W2125096092","https://openalex.org/W2128095147","https://openalex.org/W2132365366","https://openalex.org/W2134361367","https://openalex.org/W2140088548","https://openalex.org/W2144660856","https://openalex.org/W2144893998","https://openalex.org/W2145835533","https://openalex.org/W2146122315","https://openalex.org/W2147230623","https://openalex.org/W2150115931","https://openalex.org/W2155338842","https://openalex.org/W2157407457","https://openalex.org/W2159370421","https://openalex.org/W2159593598","https://openalex.org/W2165737898","https://openalex.org/W2170823959"],"related_works":["https://openalex.org/W2603418464","https://openalex.org/W2039427109","https://openalex.org/W33748964","https://openalex.org/W2047377282","https://openalex.org/W2089756110","https://openalex.org/W2150115931","https://openalex.org/W4246040243","https://openalex.org/W1984203498","https://openalex.org/W2300994133"],"abstract_inverted_index":{"Signaling":[0],"from":[1],"other":[2],"angiokinases":[3],"may":[4],"underlie":[5],"resistance":[6,191],"to":[7,49,67,109,192],"VEGF-directed":[8],"therapy.":[9],"We":[10],"evaluated":[11],"the":[12,140],"antitumor":[13,162],"and":[14,33,43,85,104,134,163,171],"biologic":[15],"effects":[16],"of":[17,41,92,142,145,169,183,204],"BIBF":[18,54,72,98,117,153,158,205],"1120":[19,55,73,99,118,159],"(nintedanib),":[20],"a":[21,82,110],"tyrosine":[22],"kinase":[23],"inhibitor":[24],"that":[25,97],"targets":[26],"VEGF":[27],"receptor,":[28,32],"platelet-derived":[29],"growth":[30,35,77],"factor":[31,36],"fibroblast":[34],"receptor":[37],"in":[38,70,78,86,125,152,166,190],"preclinical":[39,167],"models":[40,47,80,168],"lung":[42,170],"pancreatic":[44,172],"cancer,":[45],"including":[46,123],"resistant":[48],"VEGF-targeted":[50],"treatments.":[51],"In":[52,156],"vitro,":[53],"did":[56,62],"not":[57,150,179],"show":[58],"antiproliferative":[59],"effects,":[60,122],"nor":[61],"it":[63,175],"sensitize":[64],"tumor":[65,76,93],"cells":[66],"chemotherapy.":[68,90],"However,":[69],"vivo":[71],"inhibited":[74],"primary":[75],"all":[79],"as":[81],"single":[83],"agent":[84],"combination":[87],"with":[88],"standard":[89],"Analysis":[91],"tissue":[94],"posttreatment":[95],"revealed":[96],"reduced":[100],"proliferation":[101],"(phospho-histone":[102],"3)":[103],"elevated":[105,151],"apoptosis":[106],"(cleaved":[107],"caspase-3)":[108],"greater":[111],"extent":[112],"than":[113],"chemotherapy":[114],"alone.":[115],"Furthermore,":[116],"showed":[119,160],"potent":[120,161],"antiangiogenic":[121,164,193],"decreases":[124],"microvessel":[126],"density":[127],"(CD31),":[128],"pericyte":[129],"coverage":[130],"(NG2),":[131],"vessel":[132],"permeability,":[133],"perfusion,":[135],"while":[136],"increasing":[137],"hypoxia.":[138],"Despite":[139],"induction":[141],"hypoxia,":[143],"markers":[144],"epithelial-to-mesenchymal":[146],"transition":[147],"(EMT)":[148],"were":[149],"1120-treated":[154],"tumors.":[155],"summary,":[157],"activity":[165],"cancer":[173],"where":[174],"induced":[176],"hypoxia":[177],"but":[178],"EMT.":[180],"The":[181],"absence":[182],"EMT":[184],"induction,":[185],"which":[186],"has":[187],"been":[188],"implicated":[189],"therapies,":[194],"is":[195],"noteworthy.":[196],"Together,":[197],"these":[198],"results":[199],"warrant":[200],"further":[201],"clinical":[202],"studies":[203],"1120.":[206]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2118256381","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":16},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
